Drug intelligence / Profile preview

SQIN-furosemide

Development stage: Phase 2
Lead developer: SQ Innovation
Modality: Small Molecules
Administration: Subcutaneous

Overview

SQIN-furosemide is a novel, pH-neutral formulation of furosemide specifically designed for subcutaneous administration. It has a higher concentration (30 mg/mL) than standard furosemide injection and is formulated to be less irritating to the skin. This formulation is intended to be used with a patch-pump device called SQIN-Infusor for the treatment of fluid retention (edema) in patients with heart failure or chronic kidney disease. SQIN-furosemide has similar bioavailability to intravenous furosemide and can be stored at room temperature for 24 months.

Brand names: Lasix ONYU
Other names: SQIN-Furosemide

Targets

NKCC (Sodium-potassium-chloride cotransporter)

Beyond the preview

Go deeper on SQIN-furosemide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SQIN-furosemide.

Explore the full profile